Sanofi's eczema drug is four-time blockbuster

Sanofi drug Dupixent, which Leo Pharma hopes to challenge with its tralokinumab treatment, has surpassed USD 4bn in sales.
Photo: Gonzalo Fuentes/Reuters/Ritzau Scanpix
Photo: Gonzalo Fuentes/Reuters/Ritzau Scanpix
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

The resurgence of the coronavirus in many countries has not put a damper on the growth of Sanofi's eczema drug Dupixent.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading